- Company
- CDK4/6 anticancer drug is very active in early breast cancer
- by Jung, Sae-Im Jul 24, 2023 05:25am
- The activity of CDK4/6 inhibitors in early breast cancer is not limited to Verzenio. Kisqali also presented data on adjuvant therapy after successful surgery at ASCO held in June. Although they are the same class of drugs, the clinical designs of the two drugs in early breast cancer are different in many ways. First, Verzenio was targeted for hi
- Company
- The synergy between strengths & strengths
- by Kim, Jin-Gu Jul 21, 2023 05:41am
- The number of domestic pharmaceutical companies collaborating to jointly sell drugs has increased significantly. In the past, drug co-promotion contracts were mainly concluded between multinational pharmaceutical companies and domestic pharmaceutical companies. In the pharmaceutical industry, it is interpreted as a result in which the need
- Policy
- Original for Parkinson's dz tx released are withdrawn
- by Lee, Tak-Sun Jul 21, 2023 05:41am
- Decisions are being made to withdraw from Korea one after another, citing the weakening profitability of Parkinson's disease original treatment drugs, for which generics have appeared. Early this year, following Roche Korea's Madopar, Boehringer Ingelheim Korea's Mirapex ER also decided to stop supplying. The problem is that existing patients
- Company
- Exports of botulinum in the first half rose by 26%
- by Kim, Jin-Gu Jul 21, 2023 05:41am
- In the first half of last year, exports of domestic botulinum toxin increased by 26% compared to the previous year. In particular, exports to Brazil increased significantly. In the pharmaceutical industry, analysts say that Brazil is emerging as a major exporter of domestic botulinum toxin along with China and the United States. According to
- Company
- Korean pharmas busy recruiting talent from global pharmas
- by Lee, Seok-Jun Jul 21, 2023 05:41am
- Korea's pharmaceutical and bio businesses are busy recruiting talents from multinational pharmaceutical companies to further accelerate their global entry. Handok appointed Miyeon Kim (56) as the new CEO as of July 1st. At Pfizer, the new CEO Kim worked as the Strategic Planning Manager, Product Manager, Marketing Manager, and as the
- Company
- NHIS starts RSA reevaluations for AD drug Dupixent
- by Eo, Yun-Ho Jul 21, 2023 05:40am
- Sanofi has started reevaluation negotiations for its atopic dermatitis treatment ‘Dupixent,' which has been receiving reimbursement under the RSA (Risk Sharing Agreement). According to industry sources, Dupixent’s RSA term ends on December 31st, therefore, the drug is undergoing reevaluation negotiations with the National Health Insura
- Policy
- How Scemblix received reimb without negotiations
- by Lee, Tak-Sun Jul 21, 2023 05:40am
- The chronic myeloid leukemia treatment Scemblix (asciminib, Novartis) was passed the Drug Reimbursement Evaluation Committee review for costing the same as another 3rd generation CML treatment, Iclusig (ponatinib, Otsuka), The company agreed to set its price at 100% or below the weighted average price of its therapeutic alternative to wa
- Policy
- Evrysdi also subject to prior authorization for reimb
- by Lee, Tak-Sun Jul 20, 2023 05:35am
- The Health Insurance Review and Assessment Service is expected to require the oral SMA (spinal muscular atrophy) treatment ‘Evrysdi Dry Syrup (risdiplam, Roche)’ to receive prior authorization for reimbursement. Also, HIRA is planning to reflect the prior authorization experience it has accumulated from Spinraza for Evrysdi. HIRA’s
- Policy
- The more applications for pre-screening drugs, the higher
- by Lee, Tak-Sun Jul 20, 2023 05:34am
- .. Lee Jin-soo, chairman of the Medical Review and Evaluation Committee, "If the number of applications increases, the understanding of the benefit standards also increases." It was found that the higher the number of applications for pre-screening drugs, the higher the approval rate. It is an interpretation that the approval rate increases
- Company
- MET-targeting Tepmetko lands in general hospitals in KOR
- by Eo, Yun-Ho Jul 20, 2023 05:34am
- The MET-targeted anticancer therapy ‘Tepmetko’ can now be prescribed at general hospitals in Korea. According to industry sources, ‘Tepmetko (tepotinib),’ a treatment for patients with locally advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations, passed the drug committees (DCs) of various medical inst
